Psychotropic Medication Side Effects in School-Aged Populations
The purpose of this chapter is to help inform risk-benefit analysis, treatment decision-making, and monitoring for unwanted outcomes when school-aged children are treated with psychotropic medication. This chapter reviews drugs with pediatric indications (i.e., those approved by the FDA for specific conditions and age ranges) that are currently marketed in the US and prescribed for pediatric emotional and behavioral disorders (EBDs). They include four drug classes and are presented in order of frequency of use within pediatric populations (i.e., 18 years and younger): ADHD drugs (stimulant and non-stimulant), antidepressants (ADs), second-generation antipsychotics (SGAs), and the antiepileptic drugs (AEDs) and lithium. Most of the drugs reviewed have indications for a variety of pediatric EBDs, but the AEDs are only FDA-approved for a medical condition (i.e., pediatric epilepsy). To help guide the thought processes that undergird risk-benefit analysis, a framework for stakeholder’s (e.g., prescribers, parents, school professionals) communications is provided. A set of references and web-based materials are provided to readers for additional information.
KeywordsSide effects Risk-benefit analysis Psychopharmacology Psychosocial interventions ADHD drugs Antidepressants Antipsychotics Antiepileptic drugs Lithium
- Advokat, C. D., Comaty, J. E., & Julien, R. M. (2014). A primer of drug action (13th ed.). New York, NY: Worth.Google Scholar
- American Academy of Child and Adolescent Psychiatry. (2015). Recommendations about the use of psychotropic medications for children and adolescents involved in child-serving systems. Retrieved from https://www.aacap.org/App_Themes/AACAP/docs/clinical_practice_center/systems_of_care/AACAP_Psychotropic_Medication_Recommendations_2015_FINAL.pdf.
- Barkley, R. A. (Ed.). (1998). Attention-deficit hyperactivity disorder. In A handbook for diagnosis and treatment (2nd ed.). New York: Guilford.Google Scholar
- Carlson, J. S., & Shahidullah, J. D. (2014). Best practices in assessing the effects of psychotropic medications on student performance. In P. L. Harrison & A. Thomas (Eds.), Best practices in school psychology: Systems-level services (pp. 361–374). Bethesda, MD: National Association of School Psychologists.Google Scholar
- Greenhill, L., Kollins, S., Abikoff, H., McCracken, J., Riddle, M., Swanson, J., … Skrobala, A. (2006). Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 1284–1293.CrossRefGoogle Scholar
- Hazell, P., & Mirzaie, M. (2013). Tricyclic drugs for depression in children and adolescents. Cochrane Database Systematic Reviews, 18, CD002317. https://doi.org/10.1002/14651858.cd002317.pub2.
- Ninan, A., Stewart, S. L., Theall, L., King, G., Evans, R., Baiden, P., & Brown, A. (2014). Psychotropic medication monitoring checklists: Use and utility for children in residential care. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 23, 38–47.Google Scholar
- Pisano, S., Catone, G., Lanzaro, V., Pozzi, M., Clementi, E., Iuliano, R., … Masi, G. (2016). Update on the safety of second generation antipsychotics in youths: A call for collaboration among paediatricians and child psychiatrists. Italian Journal of Pediatrics, 42. https://doi.org/10.1186/s13052-016-0259-2.
- United States Food and Drug Administration. (2016). Think it through: A guide to managing the risks and benefits of medicines. Retrieved from https://www.fda.gov/Drugs/ResourcesForYou/ucm079492.htm.